Showing 1 - 20 results of 9,211 for search '(( two ((fe decrease) OR (we decrease)) ) OR ( a ((larger decrease) OR (marked decrease)) ))', query time: 0.64s Refine Results
  1. 1
  2. 2

    The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

    Published 2025
    “…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Development of Selective and Soluble Mitochondrial Complex 1 Inhibitors Derived from Papaverine for Radiosensitization of Cancer by Ben J. Haines (22458462)

    Published 2025
    “…Papaverine and some derivatives were previously shown to inhibit mitochondrial complex 1 and decrease oxygen consumption, reversing hypoxia and radiosensitizing model tumors. …”
  12. 12

    Development of Selective and Soluble Mitochondrial Complex 1 Inhibitors Derived from Papaverine for Radiosensitization of Cancer by Ben J. Haines (22458462)

    Published 2025
    “…Papaverine and some derivatives were previously shown to inhibit mitochondrial complex 1 and decrease oxygen consumption, reversing hypoxia and radiosensitizing model tumors. …”
  13. 13
  14. 14

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  15. 15

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  16. 16

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  17. 17

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  18. 18

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  19. 19
  20. 20

    Overview of the WeARTolerance program. by Ana Beato (20489933)

    Published 2024
    “…The program integrated psychoeducational and creative activities (e.g., visual arts, cinema, music, and theatre) to explore mental health themes, with 125 teenagers and young adult participants (M = 13.70; SD = 2.06). The present mixed-method study was split into two phases with complementary objectives: 1) evaluate quantitatively the program’s impact in reducing social stigma and related outcomes; 2) explore in-depth qualitative feedback about the program. …”